{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.74","value":"4.7"},{"groupId":"OG001","spread":"23.56","value":"4.3"},{"groupId":"OG002","spread":"22.38","value":"7.6"}]}],"title":"Cycle 4 - approximately Month 4 (n=112,121,124)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.45","value":"14.6"},{"groupId":"OG001","spread":"23.86","value":"7.7"},{"groupId":"OG002","spread":"20.62","value":"9.8"}]}],"title":"Cycle 7 - approximately Month 7 (n=93,108,112)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.84","value":"17.3"},{"groupId":"OG001","spread":"22.40","value":"6.6"},{"groupId":"OG002","spread":"21.73","value":"14.5"}]}],"title":"Cycle 10 - approximately Month 10 (n=83,88,97)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.15","value":"17.3"},{"groupId":"OG001","spread":"23.78","value":"6.3"},{"groupId":"OG002","spread":"24.67","value":"11.9"}]}],"title":"Cycle 13 - approximately Month 13 (n=71,73,81)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.30","value":"18.5"},{"groupId":"OG001","spread":"28.49","value":"7.7"},{"groupId":"OG002","spread":"26.62","value":"14.4"}]}],"title":"Cycle 16 - approximately Month 16 (n=62,52,62)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}